Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986326 in Adult Participants With Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic Lupus Erythematosus
NCT06013995Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2023
- Primary completion
- Apr 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 8
01
Overview
Phase 1, randomised, double-blind trial of BMS-986326 in discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE) and systemic lupus erythematosus (SLE) (6 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Adverse Events up to 228 days, Serious Adverse Events up to 228 days and 4 more. Started Sep 2023; status: completed.
02
Drugs
BMS-986326
03
Conditions
discoid lupus erythematosus (DLE)subacute cutaneous lupus erythematosus (SCLE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06013995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06013995.